Custom RNA-LNP Formulation

RNA-LNPs (RNA–lipid nanoparticles) are nanoscale delivery systems composed of four key lipid components: ionizable lipids, cholesterol (sterol), phospholipids, and PEG-lipids. They are specifically engineered to encapsulate and deliver nucleic acids such as mRNA or siRNA.

RNA-LNPs are considered the gold standard for nucleic acid delivery because they:

• Protect sensitive RNA cargo from enzymatic degradation
• Facilitate efficient cellular uptake and endosomal escape
• Can be tailored in size, charge, and composition to optimize efficacy, safety, and biodistribution

These unique features positioned RNA-LNPs as the critical enabler of the unprecedented success of mRNA COVID-19 vaccines

LNPs can encapsulate hydrophilic, charged, or fragile biomolecules or nucleic acids, including:

• mRNA, saRNA, CircRNA (vaccines, protein replacement therapies)
• siRNA, miRNA, ASO (gene silencing, oncology, rare diseases)
• DNA (gene editing, gene therapy)
• CRISPR-Cas components (RNPs or mRNA + gRNA)
• Small hydrophilic drugs
• Peptides / proteins

Thanks to our partnership with Corden Pharma, we have access to a broad range of GMP-grade lipids including

• Ionizable/Cationic Lipids: ALC-0315 (Acuitas/BioNTech – Pfizer), SM-102 (Moderna), LP-01 (Novartis – Intellia), DOTAP, DODMA & more.
• Phospholipid: DSPC, DOPE
• Sterol Lipids: Cholesterol, β-Sitosterol
• PEG-lipid: MPEG-2000-DMG, ALC-0159

Optimizing the biodistribution and tissue specifity of RNA-LNPs can be achieved through two main strategies:

1. Passive targeting
By tuning intrinsic LNP properties—such as particle size, lipid composition, and lipid ratios—the natural distribution of RNA-LNPs in the body can be influenced.
It’s the most straightforward approach but requires broad screening of lipid formulations to identify optimal profiles

2. Active targeting
By decorating LNPs with targeting ligands (e.g., antibodies, peptides, aptamers), delivery can be directed toward specific tissues or cell types.
It’s an overall more complex design and validation process but enables a more precise, tissue-specific delivery.
Active targeting

Yes. Our team works exclusively with widely available lipid mixes and our cutting-edge formulation equipment, ensuring that the process is fully reproducible in your lab.
We can then provide:

• Training sessions for your team
• Protocols and documentation
• Equipment and materials

This way, you can seamlessly internalize and scale the process once the initial collaboration is complete.

Getting started is simple. The typical workflow follows four steps:

1. Contact us — Share the context of your request and your goals
2. Meet our RNA-LNP formulation specialist — We’ll discuss your project in detail and suggest an action plan according to your target
3. Receive a quotation — Tailored to your project scope
4. Project launch — Execution following your request with our equipment and expertise
5. Quick Delivery — Results, data, and/or equipment provided as agreed